Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Arch Bronconeumol ; 47(3): 134-7, 2011 Mar.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-21392876

RESUMO

INTRODUCTION: Lung metastases originating from tumours of the female genital tract are rare. Due to this rarity and their variable histology, it has been difficult to compare different patient series. MATERIAL AND METHODS: A retrospective study of patients undergoing resection of lung metastases of female genital tract tumours (uterine and cervical cancer) during the period 01/01/1989 to 12/31/2006. Epidemiological, diagnostic and treatment data were collected. Non-parametric tests and survival analysis were performed using the Kaplan-Meier and log-rank test. RESULTS: A resection was performed on 27 patients during the study period. Disease-free interval (DFI) from initial diagnosis of lung metastases was 58 months (1-195 months). The median survival from diagnosis of metastases was 94 months. The overall survival at 5 years after diagnosis of metastasis was 84.1%. A second surgery of metastases was performed on 5 patients (18.5%). Survival after second surgery of metastases: 80.5 months. Survival from diagnosis of metastasis at five years: endometrial carcinoma 100%, cervical cancer 62.5%, uterine sarcoma 60%. Adjuvant hormonal therapy was prescribed in 15 out of 16 patients with endometrial carcinoma. There was a statistically significant difference in the survival depending on the histological type and disease free interval. CONCLUSION: Surgical treatment of lung metastases originating from female genital tract tumours (mainly endometrial carcinoma) is associated with a high long-term survival.


Assuntos
Carcinoma/secundário , Carcinoma/cirurgia , Neoplasias Pulmonares/secundário , Neoplasias Pulmonares/cirurgia , Pneumonectomia/métodos , Sarcoma/secundário , Sarcoma/cirurgia , Neoplasias do Colo do Útero/patologia , Neoplasias Uterinas/patologia , Adulto , Idoso , Antineoplásicos Hormonais/uso terapêutico , Carcinoma/tratamento farmacológico , Carcinoma/mortalidade , Quimioterapia Adjuvante , Terapia Combinada , Intervalo Livre de Doença , Neoplasias do Endométrio/tratamento farmacológico , Neoplasias do Endométrio/mortalidade , Neoplasias do Endométrio/secundário , Neoplasias do Endométrio/cirurgia , Feminino , Humanos , Estimativa de Kaplan-Meier , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/mortalidade , Excisão de Linfonodo , Pessoa de Meia-Idade , Reoperação , Estudos Retrospectivos , Sarcoma/tratamento farmacológico , Sarcoma/mortalidade , Neoplasias do Colo do Útero/tratamento farmacológico , Neoplasias Uterinas/tratamento farmacológico
2.
Arch. bronconeumol. (Ed. impr.) ; 47(3): 134-137, mar. 2011. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-88486

RESUMO

IntroducciónLos tumores del tracto genital femenino constituyen una etiología poco frecuente de metástasis pulmonares. Debido a esto y a su variada histología, la comparación de resultados ha resultado complicada hasta la fecha.Material y métodosEstudio retrospectivo de pacientes intervenidos de metástasis pulmonares de tumores del tracto genital femenino (cuerpo, trompa y cuello de útero) en el periodo 01/01/1989–31/12/2006. Se recogen datos referentes a aspectos epidemiológicos, de diagnóstico y tratamiento. Se han utilizado tests no paramétricos, y el análisis de supervivencia se ha realizado con curvas de Kaplan-Meier y el log-rank test.ResultadosDurante el periodo descrito se ha intervenido a 27 pacientes. Intervalo libre de enfermedad (ILE) desde el diagnóstico inicial al de metástasis pulmonares 58 meses (1-195 meses). Mediana de supervivencia desde el diagnóstico de metástasis 94 meses. Supervivencia global tras diagnóstico de metástasis a 5 años: 84,1%. Segunda cirugía de metástasis: 5 pacientes (18,5%). Supervivencia tras segunda cirugía de metástasis: 80,5 meses. Supervivencia desde el diagnóstico de metástasis a 5 años: carcinoma de endometrio 100%; cáncer de cérvix 62,5%; sarcoma uterino 60%. Recibieron hormonoterapia adyuvante 15 de 16 pacientes con carcinoma de endometrio. Hallamos diferencias estadísticamente significativas en la supervivencia en función de: tipo histológico, e intervalo libre de enfermedad.ConclusiónEl tratamiento quirúrgico de las metástasis del tracto genital femenino (principalmente de las de carcinoma de endometrio) se asocia a una elevada supervivencia a largo plazo(AU)


IntroductionLung metastases originating from tumours of the female genital tract are rare. Due to this rarity and their variable histology, it has been difficult to compare different patient series.Material and MethodsA retrospective study of patients undergoing resection of lung metastases of female genital tract tumours (uterine and cervical cancer) during the period 01/01/1989 to 12/31/2006. Epidemiological, diagnostic and treatment data were collected. Non-parametric tests and survival analysis were performed using the Kaplan-Meier and log-rank test.ResultsA resection was performed on 27 patients during the study period. Disease-free interval (DFI) from initial diagnosis of lung metastases was 58 months (1-195 months). The median survival from diagnosis of metastases was 94 months. The overall survival at 5 years after diagnosis of metastasis was 84.1%. A second surgery of metastases was performed on 5 patients (18.5%). Survival after second surgery of metastases: 80.5 months. Survival from diagnosis of metastasis at five years: endometrial carcinoma 100%, cervical cancer 62.5%, uterine sarcoma 60%. Adjuvant hormonal therapy was prescribed in15 out of 16 patients with endometrial carcinoma. There was a statistically significant difference in the survival depending on the histological type and disease free interval.ConclusionSurgical treatment of lung metastases originating from female genital tract tumours (mainly endometrial carcinoma) is associated with a high long-term survival(AU)


Assuntos
Humanos , Neoplasias dos Genitais Femininos/patologia , Neoplasias Pulmonares/cirurgia , Metástase Neoplásica , Neoplasias Pulmonares/secundário , Estudos Retrospectivos , Intervalo Livre de Doença
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...